Antianemia Drug Roxadustat (FG-4592) Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways

Antianemia Drug Roxadustat (FG-4592) Protects Against Doxorubicin-Induced Cardiotoxicity by Targeting Antiapoptotic and Antioxidative Pathways

Doxorubicin (DOX) is broadly used in treating various malignant tumors. However, its cardiotoxicity limits its clinical use. Roxadustat (FG-4592) is a new hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor and has been approved for treating anemia in chronic kidney diseases (CKD) patien...

Full description

Bibliographic Details
Main Authors: Guangfeng Long, Hongbing Chen, Mengying Wu, Yuanyuan Li, Ling Gao, Songming Huang, Yue Zhang, Zhanjun Jia, Weiwei Xia
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Pharmacology
Subjects:
Roxadustat
doxorubicin cardiotoxicity
HIF-1α
apoptosis
oxidative stress
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.01191/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2020.01191/full

Similar Items